First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

Phase 1

Completed

• Conditions: Diabetic Macular Edema
• Interventions: Drug: Placebo; Drug: CU06-1004, Multiple doses; Drug: CU06-1004, Single dose

• Registration Number: NCT04795037
• Lead Sponsor: Curacle Co., Ltd.

Brief Summary

This clinical trial is the first-in-human study of CU06-1004. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-03-05
• Study First Submitted QC: 2021-03-10
• Study First Posted: 2021-03-12
• Study Start: 2021-07-15
• Primary Completion: 2022-03-02
• Study Completion: 2022-06-25
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-18
• Last Update Posted: 2022-07-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 81

Inclusion Criteria

1. Healthy, adult, male or female (of non-childbearing potential only), 19-55 years of age, inclusive, at screening.

2. Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 at screening.

3. Continuous non-smoker who has not used nicotine-containing products for at least 3 months prior to the first dosing and throughout the study, based on subject self-reporting.

4. Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs or ECGs, as deemed by the PI or designee.

5. Female must be of non-childbearing potential and must have undergone one of the following sterilization procedures at least 6 months prior to the first dosing:

   • hysteroscopic sterilization;
   • bilateral tubal ligation or bilateral salpingectomy;
   • hysterectomy;
   • bilateral oophorectomy; or be postmenopausal with amenorrhea for at least 1 year prior to the first dosing and follicle-stimulating hormone (FSH) serum levels consistent with postmenopausal status.

6. A non-vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 90 days after the last dosing.

   (No restrictions are required for a vasectomized male provided his vasectomy has been performed 4 months or more prior to the first dosing. A male who has been vasectomized less than 4 months prior to the first dosing must follow the same restrictions as a non-vasectomized male).

7. If male, must agree not to donate sperm from the first dosing until 90 days after the last dosing.

8. Able to swallow multiple capsules.

9. Understands the study procedures in the informed consent form (ICF), and be willing and able to comply with the protocol.

Exclusion Criteria

1. Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.

2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.

3. History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

4. History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.

5. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.

6. Female subjects of childbearing potential.

7. Female subjects with a positive pregnancy test at screening or first check-in or who are lactating.

8. Positive urine drug or alcohol results at screening or first check-in.

9. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV).

10. Seated blood pressure is less than 90/40 mmHg or greater than 140/90 mmHg, at screening.

11. Seated heart rate is lower than 40 bpm or higher than 99 bpm at screening.

12. QTcF interval is >460 msec (males) or >470 msec (females) or has ECG findings deemed abnormal with clinical significance by the PI or designee at screening.

13. Unable to refrain from or anticipates the use of:

    • Any drug, including prescription and non-prescription medications, herbal remedies, or vitamin supplements (especially sulforaphane-containing supplement) beginning 14 days prior to the first dosing and throughout the study. After randomization, acetaminophen (up to 2 g per 24 hours) may be administered at the discretion of the PI or designee.
    • Food and beverages containing xanthines/caffeine for 24 hours prior to the first dosing (small amounts of caffeine derived from normal foodstuffs e.g.,250 mL/8 oz./1 cup decaffeinated coffee or other decaffeinated beverage, per day, with the exception of espresso; 45 g/1.5 oz. chocolate bar, per day, would not be considered a deviation to this restriction).
    • Food and beverages containing alcohol for 48 hours prior to the first dosing.
    • Food and beverages containing grapefruit/Seville orange for 14 days prior to the first dosing.
    • Food and beverages containing vegetables from the mustard green family (e.g., kale, broccoli, watercress, collard greens, kohlrabi, Brussels sprouts, mustard) and charbroiled meats for 14 days prior to the first dosing.

14. Has received COVID-19 vaccine within 30 days of first dosing and until the end of the study.

15. Has been on a diet incompatible with the on-study diet, in the opinion of the PI or designee, within the 30 days prior to the first dosing and throughout the study.

16. Is lactose intolerant (FE cohort only).

17. Donation of blood or significant blood loss within 56 days prior to the first dosing.

18. Plasma donation within 7 days prior to the first dosing.

19. Participation in another clinical study within 30 days prior to the first dosing. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to the first dose of study drug in the current study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Placebo for SAD	Placebo	* Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts * 2 of out 8 subjects per cohort will be randomized to receive placebo
Placebo for MAD	Placebo	* Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts * 2 of out 8 subjects per cohort will be randomized to receive placebo
CU06-1004 for MAD	CU06-1004, Multiple doses	* Twenty-four (24) healthy subjects are planned to be enrolled in 3 cohorts * 6 of out 8 subjects per cohort will be randomized to receive CU06-1004
CU06-1004 for SAD	CU06-1004, Single dose	* Fifty-six (56) healthy subjects are planned to be enrolled in 7 cohorts * 6 of out 8 subjects per cohort will be randomized to receive CU06-1004

Primary Outcome Measures

Name	Time	Method
The number and severity of treatment emergent adverse events (TEAEs)	From the date of first dose through 7 days after the last dose	To assess the safety and tolerability of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects.

Secondary Outcome Measures

Name	Time	Method
Area under the concentration-time curve (AUC) under fed conditions	Day 1 through Day 4 (SAD)	To assess AUC of single oral dose under fed conditions
Area under the concentration-time curve (AUC)	Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)	To assess AUC of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects
Maximum plasma concentration (Cmax)	Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)	To assess Cmax of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects
Maximum plasma concentration (Cmax) under fed conditions	Day 1 through Day 4 (SAD)	To assess Cmax of single oral dose under fed conditions
Time to reach maximum plasma concentration (Tmax)	Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)	To assess Tmax of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects
Terminal elimination rate constant (Kel)	Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)	To assess Kel of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects
Terminal elimination half-life (t½)	Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)	To assess t½ of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects
Amount of unchanged drug excreted in the urine collection (Ae)	Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)	To assess Ae of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects
Renal Clearance (CLR)	Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)	To assess CLR of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects
Fraction of drug excreted unchanged in urine (Fe)	Day 1 through Day 4 (SAD), Day 1 through Day 10 (MAD)	To assess Fe of single and multiple ascending oral doses of CU06-1004 in healthy adult subjects

Trial Locations

Locations (1)

Celerion; 🇺🇸 Lincoln, Nebraska, United States